Request quotes from five PBMC suppliers and you will get five documents that look almost identical. Viability above ninety percent, healthy donors, IRB-approved consent, research grade, cryopreserved. The specifications converge because the specifications are the easy part. What separates these suppliers sits underneath the spec sheet, in decisions made before the cells were ever collected, and almost none of it appears on the quote.
Why the spec sheet cannot separate them
A viability figure tells you what fraction of cells excluded a dye at one moment, under one method, in one operator’s hands. It does not tell you when that measurement was taken, whether the population that survived is representative of the population that went in, or how those cells will behave three days into your assay. Two lots can post the same number and diverge completely on function.
This is not an argument that specifications are meaningless. It is an argument that they are table stakes, and that a diligence process which stops at the spec sheet has not started. The questions below are the ones that actually discriminate, roughly in order of how much they predict.
Where does collection happen, and do they own it
Ask whether the supplier collects the material themselves or buys it. A large part of this market resells, and a reseller cannot apply your donor criteria at the point of collection because collection already happened, for someone else, under someone else’s protocol. What they can do is filter inventory, which is a different and much weaker capability.
The follow-up question is the useful one. If you need a donor with a specific HLA genotype and a specific cytomegalovirus status, can that be scheduled as a collection, or can they only tell you whether something matching already exists in a freezer? The gap between those two answers is the gap between a supply partner and a catalogue.
Are donors characterized before collection or after
Characterization applied at the donor program level means the supplier already knows the HLA genotype, the KIR genotype and the screening status of everyone in the pool, and can select against those attributes when you ask. Characterization applied per order means somebody runs the assay on the lot you bought, and your selection criteria were never available as selection criteria at all.
Both produce a certificate. Only one lets you specify a donor.
Can you get the same donor again
This question decides more programs than any other and gets asked least. A comparability study, a dose-ranging series, a process change eighteen months into development: each of these is far cleaner if the donor is held constant, and close to uninterpretable if it is not.
Apheresis makes recall feasible because red cells are returned to the donor, so the interval before they can give again is short. Whole blood does not. A supplier with a documented repeat-collection program can support continuity; one working from banked inventory can support it only until the lot runs out. Ask what happens when it does.
How long between collection and first processing
Leukocytes begin changing as soon as they are out of the body. Granulocyte carryover rises with delay, and the cells that survive have already started responding to being in a bag. Every downstream measurement inherits that starting state, which is one of the quieter reasons two suppliers ship the same nominal product and produce different assay results.
Most of the market treats this as a shipping problem to be managed with better packaging. The suppliers who have actually solved it did so structurally, by putting collection and processing in the same operation rather than moving material between them.
What does a blank specification mean
Sometimes a line on a specification sheet is empty. The instinct is to read that as an oversight or, worse, as an implied guarantee. Neither is safe. A blank line means no threshold is published, and the correct response is to ask why.
There are honest reasons. A whole leukopak is a heterogeneous starting material, and a single viability figure across the whole unit would be close to meaningless, so some suppliers decline to publish one. OrganaBio takes that position on whole leukopak formats and says so on the product record rather than leaving the gap to be interpreted. Published thresholds appear where the material supports them, as on the peripheral blood NK cells, where post-thaw viability is listed at 85% or above, and the cord blood NK cells, where viability and CD56+ purity are each listed at 90% or above.
A supplier who publishes a number for everything, including the things that cannot honestly carry one, is telling you something about how they treat specifications generally.
Related product
Cryopreserved PBMCs. Single-donor PBMCs in current catalogue formats, with the donor record attached.
What changes when you move to GMP
Ask this before you need it. The costly failure mode in this category is qualifying a supplier at research grade, building a process around that material, and then discovering that the GMP version comes from a different donor pool under a different quality system. At that point the comparability work goes back on your timeline and the saving that justified the original choice is gone.
The question to ask is not whether they offer GMP. Most will say yes. It is whether the GMP material comes from the same donors, under the same quality system, so that moving grade does not mean re-qualifying the input.
The diligence list, condensed
| Ask | A strong answer sounds like | A weak answer sounds like |
|---|---|---|
| Do you collect this yourselves? | Named, owned collection operation | “We work with a network of partners” |
| Can you collect to my donor criteria? | Yes, scheduled as a collection, subject to availability | “We’ll check what’s in stock” |
| When is HLA typing done? | At donor program level, before you order | “We can run it on request” |
| Can I get this donor again in 18 months? | Documented recall program, scoped per program | “While stocks last” |
| How long from collection to first processing? | A specific answer, with the reason it is short | A shipping-time answer to a processing-time question |
| Why is this specification blank? | A reason, and consistency about where numbers appear | A number produced on the spot |
| Does GMP material come from the same donors? | Same pool, same quality system | “We have a GMP offering” |
What this looks like in practice
OrganaBio collects through its own apheresis subsidiary and processes within the same operation across Miami, Irvine, Hayward and San Diego. Donor characterization runs at program level rather than per order, documenting a 14-marker infectious disease screening panel, high-resolution NGS HLA genotyping across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP, and KIR genotyping. Donor selection can be scoped by genotype and other documented attributes, subject to availability, and eligible donors can be scheduled for repeat collection.
The material sits across fresh and cryopreserved leukopaks at a documented minimum of 10 billion cells per single-donor unit, cryopreserved PBMCs, and isolated T and NK populations from the same donors, in research and cGMP formats.
Frequently asked questions
What should I look for in a PBMC supplier?
Look past the specification sheet, which converges across suppliers. The questions that discriminate are whether the supplier owns collection, whether donors are characterized at program level or per order, whether the same donor can be collected from again, how long elapses between collection and first processing, and whether GMP material comes from the same donor pool under the same quality system as the research grade.
Why do two PBMC lots with the same viability behave differently?
Viability records what fraction of cells excluded a dye at one moment under one method. It does not capture whether the surviving population is representative, how long the material waited before first processing, or the donor’s HLA and KIR genotype. Any of those can move a functional result while leaving viability unchanged.
Does it matter whether a supplier collects its own material?
Yes, because a reseller cannot apply your donor criteria at the point of collection. Collection already happened under someone else’s protocol, so the most a reseller can do is filter existing inventory. Owning collection is what makes scheduling a donor to your criteria possible.
Why does repeat collection from the same donor matter?
Comparability studies, dose-ranging series and process changes are far cleaner when the donor is held constant. Apheresis makes recall feasible because red cells are returned and the donor can give again sooner. A supplier working only from banked inventory can support continuity until the lot is exhausted.
What does a blank line on a specification sheet mean?
It means no threshold is published, not that a guarantee is implied. There can be honest reasons, such as a heterogeneous whole-unit format where a single figure would be misleading. The useful signal is consistency: a supplier who publishes a number for everything, including material that cannot honestly carry one, is revealing how they treat specifications generally.
What should I ask about moving from research grade to GMP?
Ask whether the GMP material comes from the same donor pool under the same quality system, not simply whether GMP is offered. The expensive failure is qualifying at research grade, building a process on that material, then discovering the GMP version is a different input that puts comparability work back on the timeline.
Why does time between collection and processing affect my results?
Leukocytes begin changing once they are outside the body. Granulocyte carryover rises with delay and surviving cells have already begun responding to storage conditions, so every downstream measurement inherits that starting state. Suppliers who have addressed it did so by co-locating collection and processing rather than by improving packaging.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
